Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5007 - Chemotherapy in advanced cancer patients with poor performance status (PS) initiated in an integrated oncology and palliative care (PC) setting: an observational comparative study

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  End-of-life Care

Presenters

Florian Strasser

Citation

Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382

Authors

F. Strasser1, N. Kalbermatten Magaya2, D. Hehli1, M. Früh1, D. Blum3

Author affiliations

  • 1 Clinic Oncology/hematology, Dept. Internal Medicine, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 2 Internal Medicine, Cantonal Hospital, 8596 - Münsterlingen/CH
  • 3 Onkologie, Universitätsklinimum Hamburg-Eppendorf, 20246 - Hamburg/DE
More

Resources

Abstract 5007

Background

Advanced cancer patients (ACP) with poor PS often get systemic anticancer treatment (SAT). A combined PC and medical oncology structured approach involving double boarded palliative oncologists (PallOnc) is investigated.

Methods

Medical chart review over 2½ years, with locally developed (adapted from Blum D JPSM 2014) tool, of all ACP PS > 1 in a tertiary PC unit (330 pts/year, death rate 40%, length of stay [LOS] 12 days) receiving intravenous SAT (pharmacy orders). ACP with new initiated SAT were compared with continued SAT for tumor history, PS, and outcomes; in new SAT the PallOnc processes decisional process, Palliative Interventions (PIs), and primary dose reduction were analysed.

Results

Of 95 ACP receiving SAT 65 (68%) were PS > 1. In 36 ACP a new SAT was initiated, in 29 continued. Comparable were age (years, mean: 65 vs 63), gender (% female: 39 vs 43), PS (PS3/4: 64% vs 65%)), time since diagnosis of stage 4 (months, mean: 16 vs 14), number of anticancer treatment lines (mean: 2 vs 2) and LOS (days, mean: 26 vs 24). New vs continued SAT differed for tumors not responding (never PR or SD) to last chemotherapy (55% [7 PS2, 4 PS3] vs 27% [1 PS2, 2 PS3], monotherapies (67% vs 45%), death at PC unit (14% vs 41%), overall survival (1 patient alive, 1 lost-to-follow-up; days, median: 83 vs 58, mean 152 vs 128), PS at demission compared to admission (stable PS: 33% vs 24%; improved PS: 50% vs 24%), and ACP who died ≤14 days after last SAT (22% vs 14%). No G3/4 non-hematological toxicity was reported. In the new SAT group the decisional process took 11 days (median, range 0-48), explicit goals of SAT were documented in 81% (44% specific tumour-related symptoms), attitude towards SAT in 86% ACP (unwilling, ambiguous 4/31, wants, imperative 17) and 42% physicians (0, 15). Of 5 PIs Illness understanding, symptom control, end-of-life preparation, network & family support, spiritual needs) all were delivered in 21 ACP (58%), 4 and 3 in 7, 2 in 1. Primary dose reduction was applied in 2/4 PS4 patients (1: 5-25%,1: 26-50%), 13/19 PS3 (5, 8) and 11/13 PS2 (7, 4) ACP.

Conclusions

In a setting with PallOnc anticancer treatment in poor PS patients seems feasible. The encouraging data may foster prospective research.

Clinical trial identification

Legal entity responsible for the study

Cantonal Hospital St.Gallen, Switzerland

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.